- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01830335
Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress
The Influence of Cerebral Blood Flow and Alkalosis on Neuromuscular Function During Environmental Stress
Environmental stress, such as low oxygen availability (hypoxia), has been associated with impaired neuromuscular performance; however, the mechanisms associated with these performance decrements remain unclear. While the majority of research suggests that the observed fatigue is related to the central nervous system, the influence of changes in cerebral blood flow (CBF) and associated changes in cerebral pH (partial pressure of carbon dioxide; PCO2) remains unexamined. In response to hypoxic stress, humans hyperventilate to maintain oxygen consumption, resulting in a hypocapnia mediated decrease in CBF and cerebral alkalosis (decreased PCO2). Previous research suggests that hyperventilation induces changes in neural excitability and synaptic transmission; however, it remains unclear if these changes are related to hypocapnia mediated decrease in CBF or cerebral alkalosis or both.
The purpose of the proposed research program is to examine the influence of changes in CBF and cerebral alkalosis on neuromuscular function during environmental stress. The research program will consist of 2 separate projects, summarized below in a table outlining the proposed protocols and resultant physiological manipulations. During each manipulation, neuromuscular function will be evaluated and compared to baseline (normoxic) conditions using a repeated measures design.
The research program will consist of 2 separate projects. Project 1 will examine the changes in CBF and alkalosis by using (a) indomethacin (decrease CBF; no change PCO2) and (b) hypocapnia (decrease CBF; decrease PCO2). Using a similar experimental design, Project 2 will examine the change in CBF and alkalosis during hypoxia by using (a) poikilocapnic hypoxia (decrease PO2; decrease CBF; decrease PCO2), (b) isocapnic hypoxia (decrease PO2; no change CBF; no change PCO2) and (c) isocapnic hypoxia + indomethacin (decrease PO2; decrease CBF; no change PCO2). During each manipulation, neuromuscular function will be evaluated and compared to baseline (normoxic) conditions using a repeated measures design.
Therefore, Project 1 will examine the separate and combined effect of changes in CBF and cerebral alkalosis on neuromuscular function independent of environmental manipulations. Subsequently, Project 2 will examine neuromuscular function during hypoxia while controlling CBF and cerebral alkalosis. It is hypothesized that changes in PCO2 and therefore, changes in cerebral alkalosis will contribute to neuromuscular fatigue independent of changes in CBF and oxygen availability.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
Ontario
-
St Catharines, Ontario, Canada, L2S 3A1
- Brock University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- 18 to 25 yrs old; healthy males
Exclusion Criteria:
- diagnosed medical condition; NSAID allergy; smoker; high altitude exposure; implants
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Drug
Indomethacin 1.2 mg kg 1 dose
|
|
|
Comparateur placebo: Placebo
flour capsule
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Seuil moteur au repos
Délai: Changement par rapport à la ligne de base 90 minutes
|
Les potentiels évoqués moteurs sont enregistrés à partir des muscles suite à une stimulation magnétique transcrânienne du cortex moteur.
Le seuil moteur au repos est défini comme l'intensité de stimulation minimale requise pour déclencher un potentiel évoqué moteur.
Le seuil du moteur au repos sera quantifié en millivolts.
|
Changement par rapport à la ligne de base 90 minutes
|
|
Contraction volontaire maximale
Délai: Changement par rapport à la ligne de base 90 minutes
|
Lors des tests de contraction maximale volontaire (MVC), le bras droit des participants sera fixé dans un dispositif sur mesure utilisé pour isoler la flexion de l'avant-bras et pour mesurer la production de force par le muscle fléchisseur radial du carpe.
Les participants seront invités à produire un MVC de 5 secondes et seront verbalement encouragés à maintenir une production de force maximale pendant toute la durée de la contraction.
MVC sera quantifié comme la production de force maximale en newton mètres.
|
Changement par rapport à la ligne de base 90 minutes
|
|
H-Reflex Amplitude
Délai: Change from baseline 90-minutes
|
The H-Reflex is an indirect measure of motor neuron excitability.
Initially, a maximal M-wave (M-max) will be elicited by stimulating (1 ms in duration; 15 s between stimuli) the median nerve incrementally (2 V increments) until the largest waveform is observed.
The peak-to-peak amplitude of this waveform is considered M-max.
Using similar procedures as above, a sub-maximal M-wave of 5% M-max will be elicited and the amplitude of the resultant H-reflex (a small waveform observed following the submaximal M-wave) will be calculated.
The amplitude of the H-reflex will be quantified in milllivolts.
|
Change from baseline 90-minutes
|
|
H-reflex latency
Délai: Change from baseline 90-minutes
|
The H-Reflex is an indirect measure of motor neuron excitability.
Initially, a maximal M-wave (M-max) will be elicited by stimulating (1 ms in duration; 15 s between stimuli) the median nerve incrementally (2 V increments) until the largest waveform is observed.
The peak-to-peak amplitude of this waveform is considered M-max.
Using similar procedures as above, a sub-maximal M-wave of 5% M-max will be elicited and the amplitude of the resultant H-reflex (a small waveform observed following the submaximal M-wave) will be calculated.
The onset latency of the H-reflex will be quantified in milliseconds.
|
Change from baseline 90-minutes
|
|
Voluntary Activation
Délai: Change from baseline 90-minutes
|
The level of neural drive to muscle during contraction is termed voluntary activation and will be estimated by interpolation of a single supramaximal motor evoked potential during the 5-second MVC contraction.
If extra force is evoked by the 'superimposed' stimulus then either the stimulated axons were not all recruited voluntarily or they were discharging at sub-tetanic rates.
Therefore, voluntary activation will be quantified as the amplitude of maximal voluntary force production, relative to the amplitude of the supramaximal MEP.
|
Change from baseline 90-minutes
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Vitesse du flux sanguin de l'artère cérébrale moyenne
Délai: Changement par rapport à la ligne de base 90 minutes
|
La vitesse du flux sanguin de l'artère cérébrale moyenne (MCA) sera mesurée de manière non invasive par une sonde à ultrasons Doppler transcrânien (TCD) de 2 MHz, attachée bilatéralement à un bandeau confortable et fixée en avant de l'arc zygomatique, rostral du pavillon.
Les sondes Doppler seront rythmées sur les fenêtres temporelles (près de l'oreille) et resteront en place pendant toute la durée du protocole expérimental.
La vitesse MCA sera quantifiée en cm/s.
|
Changement par rapport à la ligne de base 90 minutes
|
|
Brachial Artery Blood flow
Délai: Change from baseline 90-minutes
|
Brachial artery blood flow will be measured non-invasively using a high-resolution ultrasound machine.
Participants will lie supine with their forearm extended in a comfortable position.
Blood flow measurements will be taken in the top 1/3 of the upper arm over the duration of 10 cardiac cycles (approximately 60 seconds).
Blood flow will be quantified in L/min.
|
Change from baseline 90-minutes
|
|
Internal Carotid Artery Blood Flow
Délai: Change from baseline 90-minutes
|
Internal carotid artery (ICA) blood flow will be measured non-invasively using a high-resolution ultrasound machine.
Participants will lie supine with a slight extension of the neck and at 45° of lateral flexion away from the side being scanned.
ICA measurements will be taken 1 cm superior to the common carotid bifurcation over the duration of 10 cardiac cycles (approximately 60 seconds).
Blood flow will be quantified in L/min.
|
Change from baseline 90-minutes
|
|
Blood pressure
Délai: Change from baseline 90-minutes
|
Beat by beat blood pressure will be calculated from the blood pressure waveform using finger photoplethysmography (Nexfin, bmeye), with a finger cuff placed directly over the middle finger on the left hand.
Blood pressure will be quantified in mmHg.
|
Change from baseline 90-minutes
|
|
Pulse oximetry
Délai: Change from baseline 90-minutes
|
A pulse oximetry probe will be placed over a finger to provide a continuous, non-invasive measurement of the blood oxygen saturation to confirm that the end-tidal forcing system is controlling oxygen delivery at the desired levels during each experiment.
Oxygen saturation will be quantified as a percentage.
|
Change from baseline 90-minutes
|
|
Heart Rate
Délai: Change from baseline 90-minutes
|
Heart rate will be measured by electrocardiogram.
Heart rate will be quantified in beats per minute.
|
Change from baseline 90-minutes
|
|
End-Tidal Gas Concentrations
Délai: Change from baseline 90-minutes
|
The end-tidal concentrations of oxygen and carbon dioxide will be measured and reported in mmHg.
|
Change from baseline 90-minutes
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Stephen Cheung, PhD, Brock University
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Agents du système nerveux périphérique
- Inhibiteurs d'enzymes
- Analgésiques
- Agents du système sensoriel
- Agents anti-inflammatoires non stéroïdiens
- Analgésiques, non narcotiques
- Agents anti-inflammatoires
- Agents antirhumatismaux
- Inhibiteurs de la cyclooxygénase
- Agents de contrôle de la reproduction
- Antigoutteux
- Agents tocolytiques
- Indométhacine
Autres numéros d'identification d'étude
- 12-167
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .